Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products.

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target ...

Find insight on GSK, Novo Nordisk, tariff escalation and more in the latest Market Talks covering Health Care.

The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it is alleged to have not paid a $900,000 importation tax bill ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

Symphony Ltd (BOM:517385) reports a 49% increase in standalone top line and announces strategic measures to tackle forex losses and doubtful debts.